Search

Your search keyword '"Garcia-Marco, Jose A."' showing total 277 results
Start Over Author "Garcia-Marco, Jose A."
277 results on '"Garcia-Marco, Jose A."'

1. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

Author

Abrisqueta, Pau, González-Barca, Eva, Ferrà, Christelle, Ríos-Herranz, Eduardo, Fernández de la Mata, Margarita, Delgado, Julio, Andreu, Rafael, Hernández-Rivas, José Ángel, Terol, María José, Navarro, Almudena, Vidriales, M. Belén, Baltasar, Patricia, De la Serna, Javier, Ramírez, Ángel, Ballester, Carmen, Moreno, Carol, García-Marco, José Antonio, Córdoba, Raúl, Yáñez, Lucrecia, Casado, Luís Felipe, González, Marcos, and Bosch, Francesc

Published
2024
Full Text
View/download PDF

2. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Author

Byrd, John C, Hillmen, Peter, Ghia, Paolo, Kater, Arnon P, Chanan-Khan, Asher, Furman, Richard R, O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A, Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F, Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, and Jurczak, Wojciech

Subjects
Clinical Research, Hematology, Lymphoma, Cancer, Rare Diseases, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adenine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Piperidines, Prognosis, Prospective Studies, Pyrazines, Survival Rate, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeAmong Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL).MethodsPatients with previously treated CLL with centrally confirmed del(17)(p13.1) or del(11)(q22.3) were randomly assigned to oral acalabrutinib 100 mg twice daily or ibrutinib 420 mg once daily until progression or unacceptable toxicity. The primary end point was independent review committee-assessed noninferiority of progression-free survival (PFS).ResultsOverall, 533 patients (acalabrutinib, n = 268; ibrutinib, n = 265) were randomly assigned. At the data cutoff, 124 (46.3%) acalabrutinib patients and 109 (41.1%) ibrutinib patients remained on treatment. After a median follow-up of 40.9 months, acalabrutinib was determined to be noninferior to ibrutinib with a median PFS of 38.4 months in both arms (95% CI acalabrutinib, 33.0 to 38.6 and ibrutinib, 33.0 to 41.6; hazard ratio: 1.00; 95% CI, 0.79 to 1.27). All-grade atrial fibrillation/atrial flutter incidence was significantly lower with acalabrutinib versus ibrutinib (9.4% v 16.0%; P = .02); among other selected secondary end points, grade 3 or higher infections (30.8% v 30.0%) and Richter transformations (3.8% v 4.9%) were comparable between groups and median overall survival was not reached in either arm (hazard ratio, 0.82; 95% CI, 0.59 to 1.15), with 63 (23.5%) deaths with acalabrutinib and 73 (27.5%) with ibrutinib. Treatment discontinuations because of adverse events occurred in 14.7% of acalabrutinib-treated patients and 21.3% of ibrutinib-treated patients.ConclusionIn this first direct comparison of less versus more selective Bruton's tyrosine kinase inhibitors in CLL, acalabrutinib demonstrated noninferior PFS with fewer cardiovascular adverse events.

Published
2021

3. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Author

Roeker, Lindsey E., Eyre, Toby A., Thompson, Meghan C., Lamanna, Nicole, Coltoff, Alexander R., Davids, Matthew S., Baker, Peter O., Leslie, Lori, Rogers, Kerry A., Allan, John N., Cordoba, Raul, Lopez-Garcia, Alberto, Antic, Darko, Pagel, John M., Martinez-Calle, Nicolas, García-Marco, José Antonio, Hernández‐Rivas, Jose‐Ángel, Miras, Fatima, Coombs, Catherine C., Österborg, Anders, Hansson, Lotta, Seddon, Amanda N., López Jiménez, Javier, Wilson, Matthew R., El-Sharkawi, Dima, Wojenski, Daniel, Ma, Shuo, Munir, Talha, Valenciano, Susana, Seymour, Erlene, Barr, Paul M., Pu, Jeffrey, Patten, Piers E.M., Perini, Guilherme F., Huntington, Scott F., Parry, Helen, Sundaram, Suchitra, Skarbnik, Alan, Kamdar, Manali, Jacobs, Ryan, Walter, Harriet, Walewska, Renata, Broom, Angus, Lebowitz, Sonia, Isaac, Krista M., Portell, Craig A., Ahn, Inhye E., Ujjani, Chaitra S., Shadman, Mazyar, Skånland, Sigrid S., Chong, Elise A., and Mato, Anthony R.

Published
2021
Full Text
View/download PDF

4. Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Author

Mato, Anthony R., Roeker, Lindsey E., Lamanna, Nicole, Allan, John N., Leslie, Lori, Pagel, John M., Patel, Krish, Osterborg, Anders, Wojenski, Daniel, Kamdar, Manali, Huntington, Scott F., Davids, Matthew S., Brown, Jennifer R., Antic, Darko, Jacobs, Ryan, Ahn, Inhye E., Pu, Jeffrey, Isaac, Krista M., Barr, Paul M., Ujjani, Chaitra S., Geyer, Mark B., Berman, Ellin, Zelenetz, Andrew D., Malakhov, Nikita, Furman, Richard R., Koropsak, Michael, Bailey, Neil, Hanson, Lotta, Perini, Guilherme F., Ma, Shuo, Ryan, Christine E., Wiestner, Adrian, Portell, Craig A., Shadman, Mazyar, Chong, Elise A., Brander, Danielle M., Sundaram, Suchitra, Seddon, Amanda N., Seymour, Erlene, Patel, Meera, Martinez-Calle, Nicolas, Munir, Talha, Walewska, Renata, Broom, Angus, Walter, Harriet, El-Sharkawi, Dima, Parry, Helen, Wilson, Matthew R., Patten, Piers E.M., Hernández-Rivas, José-Ángel, Miras, Fatima, Fernández Escalada, Noemi, Ghione, Paola, Nabhan, Chadi, Lebowitz, Sonia, Bhavsar, Erica, López-Jiménez, Javier, Naya, Daniel, Garcia-Marco, Jose Antonio, Skånland, Sigrid S., Cordoba, Raul, and Eyre, Toby A.

Published
2020
Full Text
View/download PDF

5. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Scarfò, Lydia, Chatzikonstantinou, Thomas, Rigolin, Gian Matteo, Quaresmini, Giulia, Motta, Marina, Vitale, Candida, Garcia-Marco, Jose Antonio, Hernández-Rivas, José Ángel, Mirás, Fatima, Baile, Mónica, Marquet, Juan, Niemann, Carsten U., Reda, Gianluigi, Munir, Talha, Gimeno, Eva, Marchetti, Monia, Quaglia, Francesca Maria, Varettoni, Marzia, Delgado, Julio, Iyengar, Sunil, Janssens, Ann, Marasca, Roberto, Ferrari, Angela, Cuéllar-García, Carolina, Itchaki, Gilad, Špaček, Martin, De Paoli, Lorenzo, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Mauro, Francesca R., Šimkovič, Martin, Van Der Spek, Ellen, Vandenberghe, Elisabeth, Trentin, Livio, Wasik-Szczepanek, Ewa, Ruchlemer, Rosa, Bron, Dominique, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Farina, Lucia, Foglietta, Myriam, Gentile, Massimo, Herishanu, Yair, Herold, Tobias, Jaksic, Ozren, Kater, Arnon P., Kersting, Sabina, Malerba, Lara, Orsucci, Lorella, Popov, Viola Maria, Sportoletti, Paolo, Yassin, Mohamed, Pocali, Barbara, Barna, Gabor, Chiarenza, Annalisa, dos Santos, Gimena, Nikitin, Eugene, Andres, Martin, Dimou, Maria, Doubek, Michael, Enrico, Alicia, Hakobyan, Yervand, Kalashnikova, Olga, Ortiz Pareja, Macarena, Papaioannou, Maria, Rossi, Davide, Shah, Nimish, Shrestha, Amit, Stanca, Oana, Stavroyianni, Niki, Strugov, Vladimir, Tam, Constantine, Zdrenghea, Mihnea, Coscia, Marta, Stamatopoulos, Kostas, Rossi, Giuseppe, Rambaldi, Alessandro, Montserrat, Emili’, Foà, Robin, Cuneo, Antonio, and Ghia, Paolo

Published
2020
Full Text
View/download PDF

7. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Author

Aboulafia, David, Advani, Ranjana, Alpdogan, Onder, Ando, Kiyoshi, Arcaini, Luca, Baldini, Luca, Bellam, Naresh, Bartlett, Nancy, Belada, David, Yehuda, Dina Ben, Benedetti, Fabio, Borchman, Peter, Bordessoule, Dominique, Brice, Pauline, Briones, Javier, Caballero, Dolores, Carella, Angelo Michele, Chang, Hung, Cheong, June Weon, Cho, Seok-Goo, Choi, Ilseung, Choquet, Sylvain, Colita, Andrei, Congui, Angela Giovanna, D'amore, Francesco, Dang, Nam, Davison, Kelly, de Guibert, Sophie, Brown, Peter de Nully, Delwail, Vincent, Demeter, Judit, di Raimondo, Francesco, Do, Young Rok, Domingo, Eva, Douvas, Michael, Dreyling, Martin, Ernst, Thomas, Fanale, Michelle, Fay, Keith, Feldman, Tatyana, Ferrero, Silvia Fernandez, Flinn, Ian Winchester, Forero-Torres, Andres, Fox, Christopher, Friedberg, Jonathan, Fukuhara, Noriko, Garcia-Marco, Jose, Cruz, Jorge Gayoso, Codina, Jose Gomez, Gressin, Remy, Grigg, Andrew, Gurion, Ronit, Christensen, Jacob Haaber, Haioun, Corinne, Hajek, Roman, Hanel, Mathias, Hatake, Kiyohiko, Hensen, Robert, Horowitz, Netanel, Horwitz, Steven, Huttmann, Andreas, Illes, Arpad, Illidge, Tim, Ishizawa, Kenichi, Islas-Ohlmayer, Miguel, Jacobsen, Eric, Janakiram, Murali, Jurczak, Wojciech, Kaminski, Mark, Kato, Koji, Kim, Won Seog, Kirgner, Ilya, Iyer, Swaminathan, Kuo, Ching-Yuan, Lazaroiu, Mihaela Cornelia, Du, Katell Le, Lee, Jong-Seok, LeGouill, Steven, Lennard, Anne, LaRosee, Paul, Levi, Itai, Link, Brian, Maisonneuve, Herve, Maruyama, Dai, Mayer, Jiri, McCarty, John, McKay, Pam, Minami, Yosuke, Mocikova, Heidi, Morra, Enrica, Morschhauser, Franck, Munoz, Javier, Nagai, Hirokazu, O'Connor, Owen, Opat, Stephen, Pettengell, Ruth, Pezzutto, Antonio, Pfreundschuh, Michael, Pluta, Andrzej, Porcu, PierLuigi, Pro, Barbara, Quach, Hang, Rambaldi, Alessandro, Renwick, William, Reyes, Ruben, Izquierdo, Antonia Rodriguez, Rossi, Giuseppe, Ruan, Jia, Rusconi, Chiara, Salles, Gilles, Santoro, Armando, Sarriera, Jose, Savage, Kerry, Shibayama, Hirohiko, Shustov, Andrei, Suh, Cheolwon, Sureda, Anna, Tanimoto, Mitsune, Taniwaki, Masafumi, Tilly, Herve, Tobinai, Kensei, Trneny, Marek, Trumper, Lorenz, Tsukamoto, Norifumi, Tsukasaki, Kunihiro, Vitolo, Umberto, Walewski, Jan, Weidmann, Eckhart, Wilhelm, Martin, Witzens-Harig, Mathias, Yacoub, Abdulraheem, Yamamoto, Kazuhito, Yeh, Su-Peng, Yoon, Sung-Soo, Yuen, Sam, Yun, Hwan Jung, Zain, Jasmine, Zinzani, Pier Luigi, O'Connor, Owen A, Bartlett, Nancy L, Domingo-Domenech, Eva, Illés, Árpád, Hüttmann, Andreas, Savage, Kerry J, Hua, Zhaowei, Little, Meredith, Rao, Shangbang, Woolery, Joseph, Manley, Thomas, and Trümper, Lorenz

Published
2019
Full Text
View/download PDF

10. P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY

Author

Munir, Talha, primary, Shadman, Mazyar, additional, Robak, Tadeusz, additional, R. Brown, Jennifer, additional, Kahl, Brad, additional, Ghia, Paolo, additional, Giannopoulos, Krzysztof, additional, Simkovic, Martin, additional, Österberg, Anders, additional, Laurenti, Luca, additional, Walker, Patricia, additional, Opat, Stephen, additional, Ciepluch, Hanna, additional, Greil, Richard, additional, Hanna, Merit, additional, Tani, Monica, additional, Trneny, Marek, additional, M. Brander, Danielle, additional, W. Flinn, Ian, additional, Grosicki, Sebastian, additional, Verner, Emma, additional, Tedeschi, Alessandra, additional, De Guibert, Sophie, additional, Tumyan, Gayane, additional, Laribi, Kamel, additional, Antonio Garcia Marco, Jose, additional, LI, Jianyong, additional, Tian, Tian, additional, Ramakrishnan, Vanitha, additional, Liu, Yu, additional, Szeto, Andy, additional, Paik, Jason, additional, Cohen, Aileen, additional, Tam, Constantine, additional, and Jurczak, Wojciech, additional

Published
2023
Full Text
View/download PDF

11. Comparative Review of the Current and Future Strategies to Evaluate Bone Marrow Infiltration at Diffuse Large B-Cell Lymphoma Diagnosis.

Author

Martin-Moro, Fernando, Lopez-Jimenez, Javier, Garcia-Marco, Jose A., and Garcia-Vela, Jose A.

Subjects
BONE marrow, CANCER diagnosis, DIFFUSE large B-cell lymphomas, POSITRON emission tomography, PROGNOSIS
Abstract

Diffuse large B-cell lymphoma (DLBCL) requires a complete staging at diagnosis that may have prognostic and therapeutic implications. The role of bone marrow (BM) biopsy (BMB) is controversial in the era of nuclear imaging techniques. We performed a comparative review of 25 studies focused on BM evaluation at DLBCL diagnosis, including at least two of the following techniques: BMB, flow cytometry, and positron emission tomography (PET-FDG). The report about BM involvement (BMi), diagnostic accuracy, and prognostic significance was collected and compared among techniques. A concordance analysis between BMB, FCM, and PET was also performed, and we deeply evaluated the implications of the different types of BMi: concordant by LBCL or discordant by low-grade B-cell lymphoma for both BMB and FCM, and focal or diffuse uptake pattern for PET. As a main conclusion, BMB, FCM, and PET are complementary tools that provide different and clinically relevant information in the assessment of BMi in newly diagnosed DLBCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders

Author

Kwon, Mi, Bautista, Guiomar, Balsalobre, Pascual, Sánchez-Ortega, Isabel, Serrano, David, Anguita, Javier, Buño, Ismael, Fores, Rafael, Regidor, Carmen, García Marco, José A., Vilches, Carlos, de Pablo, Rosario, Fernández, Manuel N., Gayoso, Jorge, Duarte, Rafael, Díez-Martín, José Luis, and Cabrera, Rafael

Published
2014
Full Text
View/download PDF

16. PLCG1 mutations in cutaneous T-cell lymphomas

Author

Vaqué, José P., Gómez-López, Gonzalo, Monsálvez, Verónica, Varela, Ignacio, Martínez, Nerea, Pérez, Cristina, Domínguez, Orlando, Graña, Osvaldo, Rodríguez-Peralto, José L., Rodríguez-Pinilla, Socorro M., González-Vela, Carmen, Rubio-Camarillo, Miriam, Martín-Sánchez, Esperanza, Pisano, David G., Papadavid, Evangelia, Papadaki, Theodora, Requena, Luis, García-Marco, José A., Méndez, Miriam, Provencio, Mariano, Hospital, Mercedes, Suárez-Massa, Dolores, Postigo, Concepción, San Segundo, David, López-Hoyos, Marcos, Ortiz-Romero, Pablo L., Piris, Miguel A., and Sánchez-Beato, Margarita

Published
2014
Full Text
View/download PDF

17. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, primary, Scarfò, Lydia, additional, Chatzikonstantinou, Thomas, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Andres, Martin, additional, Antic, Darko, additional, Allsup, David, additional, Baile, Mónica, additional, Bron, Dominique, additional, Capasso, Antonella, additional, Catherwood, Mark, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Delgado, Julio, additional, Dimou, Maria, additional, Doubek, Michael, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Efstathopoulou, Maria, additional, Shimaa, El-Ashwah, additional, Enrico, Alicia, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Furstenau, Moritz, additional, Garcia-Marco, Jose A., additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Maria, Gomes da Silva, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernandez, jose Angel, additional, Herold, Tobias, additional, Iyengar, Sunil, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Olga, additional, Kalicinska, Elzbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark-David, additional, Lista, Enrico, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet Palomanes, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca Romana, additional, Mayor-Bastida, Carlota, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Milosevic, Ivana, additional, Miras Calvo, Fatima, additional, Niemann, Carsten Utoft, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Pocali, Barbara, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Raa, Doreen te, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca Ciocan, Oana, additional, Tadmor, Tamar, additional, Vandenberghe, Elisabeth, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Van Der Spek, Ellen, additional, Van Gelder, Michel, additional, Wasik-Szczepanek, Ewa, additional, Yáñez, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Eichhorst, Barbara, additional, Rambaldi, Alessandro, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2022
Full Text
View/download PDF

18. Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Author

Antic, Darko, primary, Milic, Natasa, additional, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Otasevic, Vladimir, additional, Rajovic, Nina, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Baile Gonzales, Monica, additional, Capasso, Antonella, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Correa, Juan Gonzalo, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Dimou, Maria, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Lopez-Garcia, Alberto, additional, Garcia-Marco, Jose A., additional, García-Serra, Rocío, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Gomes da Silva, Maria, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernández-Rivas, José Ángel, additional, Herold, Tobias, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Koren-Michowitz, Maya, additional, Gomez, Jorge Labrador, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Fresa, Alberto, additional, Levin, Mark-David, additional, Mayor Bastida, Carlota, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Nunes, Raquel, additional, Olivieri, Jacopo, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Stavroyianni, Niki, additional, Te Raa, Doreen, additional, Tomic, Kristina, additional, Tonino, Sanne, additional, Trentin, Livio, additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, Varettoni, Marzia, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Vukovic, Vojin, additional, Wasik-Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Yanez San Segundo, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Carrier, Marc, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2022
Full Text
View/download PDF

19. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Author

Ferra, Christelle, primary, Terol, María José, additional, Marquet Palomanes, Juan, additional, Ramírez Payer, Angel, additional, Moreno, Carol, additional, Osorio, Santiago, additional, De la Cruz, Fátima, additional, Garcia-Marco, Jose A., additional, Ortiz, Macarena, additional, Rios Herranz, Eduardo, additional, Magnano, Laura, additional, Iraheta, Sandra, additional, Puerta, Jose Manuel, additional, de la Serna, Javier, additional, Smucler, Alicia, additional, Arguiñano, Jose Maria, additional, Loscertales, Javier, additional, Muiña, Begoña, additional, Fernández, Rubén, additional, García, Tomas, additional, Márquez, José A., additional, Muntañola Prat, Ana, additional, Perez Persona, Ernesto, additional, Yáñez, Lucrecia, additional, Pérez-Encinas, Manuel, additional, González Díaz, Marcos, additional, Caballero, Gonzalo, additional, Andreu, María Angeles, additional, Andreu, Rafael, additional, Ruiz-Zorrilla, Ana, additional, Moreno, Diana, additional, and Baltasar, Patricia, additional

Published
2022
Full Text
View/download PDF

20. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

Author

Abrisqueta, Pau, Villamor, Neus, Terol, María José, González-Barca, Eva, González, Marcos, Ferrà, Christelle, Abella, Eugenia, Delgado, Julio, García-Marco, Jose A., González, Yolanda, Carbonell, Felix, Ferrer, Secundino, Monzó, Encarna, Jarque, Isidro, Muntañola, Ana, Constants, Mireia, Escoda, Lourdes, Calvo, Xavier, Bobillo, Sabela, Montoro, José Bruno, Montserrat, Emili, and Bosch, Francesc

Published
2013
Full Text
View/download PDF

22. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, Ghia, Paolo, Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2022

24. A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

Author

Lopez-Guillermo, Armando, Canales, Miguel Angel, Dlouhy, Ivan, Mercadal, Santiago, Briones, Javier, Martin Garcia-Sancho, Alejandro, Sancho, Juan Manuel, Maria Moraleda, Jose, Terol, Maria Jose, Salar, Antonio, Palomera, Luis, Gardella, Santiago, Jarque, Isidro, Ferrer, Secundino, Bargay, Joan, Lopez, Andres, Panizo, Carlos, Muntañola, Anna, Montalban, Carlos, Conde, Eulogio, Hernandez, Miguel T., Soler, Alfons, Garcia Marco, Jose A., Deben, Guillermo, Marin, Julian, and Tomas, Jose Francisco

Subjects
90Y ibritumomab tiuxetan, 90Y ibritumomab tiuxetan, Follicular lymphoma, maintenance, Follicular lymphoma, maintenance
Abstract

This is a randomized phase-2 trial aimed to compare consolidation vs. maintenance in untreated patients with follicular lymphoma (FL) responding to induction. 146 patients were enrolled from 25 Spanish institutions (ZAR2007; ClinicalTrials.gov #NCT00662948). Patients in PR or CR/CR[u] after R-CHOP were randomized 1:1 to Y-90-ibritumomab-tiuxetan 0.4 mCi/kg (arm A) vs. rituximab 375 mg/m(2) every 8 weeks for 2 years (arm B). After a median follow-up of 10.55 years, 53 patients eventually progressed with a 10-year PFS of 50% vs. 56% for patients in arm A and B, respectively (HR = 1.42; p > 0.1). No significant differences were seen in OS (10-year OS 78% vs. 84.5%; HR = 1.39, p > .1). Patients receiving Y-90-ibritumomab-tiuxetan showed higher incidence of second neoplasms than those in arm B (10-year cumulative incidence 18.5 vs. 2%, respectively; p = .038). In conclusion, in FL patients responding to R-CHOP, no significant differences were found between consolidation and maintenance, although with higher late toxicity for consolidation.

Published
2022

31. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults

Author

Gonzalo-Daganzo, Rosa, Regidor, Carmen, Martín-Donaire, Trinidad, Rico, Miguel Angel, Bautista, Guiomar, Krsnik, Isabel, Forés, Rafael, Ojeda, Emilio, Sanjuán, Isabel, García-Marco, José A., Navarro, Belén, Gil, Santiago, Sánchez, Rocío, Panadero, Nuria, Gutiérrez, Yolanda, García-Berciano, Miguel, Pérez, Nuria, Millán, Isabel, Cabrera, Rafael, and Fernández, Manuel N.

Published
2009
Full Text
View/download PDF

32. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Author

Baltasar, Patricia, primary, Terol, María José, additional, Marquet Palomanes, Juan, additional, Ramírez Payer, Angel, additional, Moreno, Carol, additional, Osorio, Santiago, additional, De la Cruz, Fátima, additional, Garcia-Marco, Jose A., additional, Ortiz, Macarena, additional, Ríos Herranz, Eduardo, additional, Magnano, Laura, additional, Iraheta, Sandra, additional, Puerta, Jose Manuel, additional, de la Serna, Javier, additional, Smucler Simonovich, Alicia, additional, Arguiñano, Jose Maria, additional, Loscertales, Javier, additional, Muiña, Begoña, additional, Fernandez, Ruben, additional, García, Tomas, additional, Márquez, José A., additional, Muntañola Prat, Ana, additional, Pérez Persona, Ernesto, additional, Yáñez, Lucrecia, additional, Pérez-Encinas, Manuel, additional, González Díaz, Marcos, additional, Caballero, Gonzalo, additional, Andreu, María Angeles, additional, Andreu, Rafael, additional, Ruiz-Zorrilla, Ana, additional, Moreno, Diana, additional, and Ferrà, Christelle, additional

Published
2021
Full Text
View/download PDF

34. Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Author

Roeker, Lindsey E, Scarfo, Lydia, Chatzikonstantinou, Thomas, Abrisqueta, Pau, Eyre, Toby A., Cordoba, Raul, Muntañola Prat, Ana, Villacampa, Guillermo, Leslie, Lori A., Koropsak, Michael, Quaresmini, Giulia, Allan, John N., Furman, Richard R., Bhavsar, Erica B, Pagel, John M., Hernandez-Rivas, Jose Angel, Patel, Krish, Motta, Marina, Bailey, Neil, Miras, Fatima, Lamanna, Nicole, Alonso, Rosalia, Osorio-Prendes, Santiago, Vitale, Candida, Kamdar, Manali, Baltasar, Patricia, Österborg, Anders, Hanson, Lotta, Baile, Mónica, Rodríguez-Hernández, Ines, Valenciano, Susana, Popov, Viola Maria, Barez Garcia, Abelardo, Alfayate, Ana, Oliveira, Ana C, Eichhorst, Barbara, Quaglia, Francesca M., Reda, Gianluigi, Lopez Jimenez, Javier, Varettoni, Marzia, Marchetti, Monia, Romero, Pilar, Riaza Grau, Rosalía, Munir, Talha, Zabalza, Amaya, Janssens, Ann, Niemann, Carsten U, Perini, Guilherme Fleury, Delgado, Julio, Yanez San Segundo, Lucrecia, Gómez Roncero, Ma Isabel, Wilson, Matthew, Patten, Piers, Marasca, Roberto, Iyengar, Sunil, Seddon, Amanda, Torres, Ana, Ferrari, Angela, Cuéllar-García, Carolina, Wojenski, Daniel, El-Sharkawi, Dima, Itchaki, Gilad, Parry, Helen, Mateos-Mazón, Juan José, Martinez-Calle, Nicolas, Ma, Shuo, Naya, Daniel, Van Der Spek, Ellen, Seymour, Erlene K., Gimeno Vázquez, Eva, Rigolin, Gian Matteo, Mauro, Francesca Romana, Walter, Harriet S, Labrador, Jorge, De Paoli, Lorenzo, Laurenti, Luca, Ruiz, Elena, Levin, Mark-David, Šimkovič, Martin, Špaček, Martin, Andreu, Rafa, Walewska, Renata, Perez-Gonzalez, Sonia, Sundaram, Suchitra, Wiestner, Adrian, Cuesta, Amalia, Broom, Angus, Kater, Arnon P., Muiña, Begoña, Velasquez, César A, Ujjani, Chaitra S., Seri, Cristina, Antic, Darko, Bron, Dominique, Vandenberghe, Elisabeth, Chong, Elise A., Lista, Enrico, García, Fiz Campoy, Del Poeta, Giovanni, Ahn, Inhye, Pu, Jeffrey J., Brown, Jennifer R, Soler Campos, Juan Alfonso, Malerba, Lara, Trentin, Livio, Orsucci, Lorella, Farina, Lucia, Villalon, Lucia, Vidal, Maria Jesus, Sanchez, Maria Jose, Terol, Maria Jose, De Paolis, Maria Rosaria, Gentile, Massimo, Davids, Matthew S., Shadman, Mazyar, Yassin, Mohamed A, Foglietta, Myriam, Jaksic, Ozren, Sportoletti, Paolo, Barr, Paul M., Ramos, Rafael, Santiago, Raquel, Ruchlemer, Rosa, Kersting, Sabina, Huntington, Scott F., Herold, Tobias, Herishanu, Yair, Thompson, Meghan C., Lebowitz, Sonia, Ryan, Christine, Jacobs, Ryan W., Portell, Craig A., Isaac, Krista, Rambaldi, Alessandro, Nabhan, Chadi, Brander, Danielle M., Montserrat, Emili, Rossi, Giuseppe, Garcia-Marco, Jose A., Sr., Coscia, Marta, Malakhov, Nikita, Fernandez-Escalada, Noemi, Skånland, Sigrid Strand, Coombs, Callie C., Ghione, Paola, Schuster, Stephen J., Foà, Robin, Cuneo, Antonio, Bosch, Francesc, Stamatopoulos, Kostas, Ghia, Paolo, Mato, Anthony R., and Patel, Meera

Published
2020
Full Text
View/download PDF

35. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas Kapetanakis, Anargyros Scarfo, Lydia and Karakatsoulis, Georgios Allsup, David Alonso Cabrero, Alejandro Andres, Martin Antic, Darko Baile, Monica and Baliakas, Panagiotis Bron, Dominique Capasso, Antonella and Chatzileontiadou, Sofia Cordoba, Raul Correa, Juan-Gonzalo and Cuellar-Garcia, Carolina De Paoli, Lorenzo De Paolis, Maria Rosaria Del Poeta, Giovanni Demosthenous, Christos Dimou, Maria Donaldson, David Doubek, Michael Efstathopoulou, Maria and Eichhorst, Barbara El-Ashwah, Shaimaa Enrico, Alicia and Espinet, Blanca Farina, Lucia Ferrari, Angela Foglietta, Myriam Frederiksen, Henrik Furstenau, Moritz Garcia-Marco, Jose A. Garcia-Serra, Rocio Gentile, Massimo Gimeno, Eva and Glenthoj, Andreas da Silva, Maria Gomes Gutwein, Odit and Hakobyan, Yervand K. Herishanu, Yair Angel Hernandez-Rivas, Jose and Herold, Tobias Innocenti, Idanna Itchaki, Gilad Jaksic, Ozren Janssens, Ann Kalashnikova, Olga B. Kalicinska, Elzbieta Karlsson, Linda Katharina Kater, Arnon P. Kersting, Sabina Labrador, Jorge Lad, Deepesh Laurenti, Luca and Levin, Mark-David Lista, Enrico Lopez-Garcia, Alberto and Malerba, Lara Marasca, Roberto Marchetti, Monia Marquet, Juan Mattsson, Mattias Mauro, Francesca R. Milosevic, Ivana and Miras, Fatima Morawska, Marta Motta, Marina Munir, Talha and Murru, Roberta Niemann, Carsten U. Rodrigues, Raquel Nunes and Olivieri, Jacopo Orsucci, Lorella Papaioannou, Maria and Arturo Pavlovsky, Miguel Piskunova, Inga Popov, Viola Maria and Quaglia, Francesca Maria Quaresmini, Giulia Qvist, Kristian and Reda, Gianluigi Rigolin, Gian Matteo Ruchlemer, Rosa and Saghumyan, Gevorg Shrestha, Amit Simkovic, Martin Spacek, Martin Sportoletti, Paolo Stanca, Oana Stavroyianni, Niki and Tadmor, Tamar Te Raa, Doreen Tonino, Sanne H. Trentin, Livio Van der Spek, Ellen van Gelder, Michel van Kampen, Roel Varettoni, Marzia Visentin, Andrea Vitale, Candida and Wasik-Szczepanek, Ewa Wrobel, Tomasz Yanez San Segundo, Lucrecia and Yassin, Mohamed Coscia, Marta Rambaldi, Alessandro and Montserrat, Emili Foa, Robin Cuneo, Antonio Stamatopoulos, Kostas Ghia, Paolo

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

Published
2021

36. Poster: CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia

Author

Byrd, John C., primary, Hillmen, Peter, additional, Ghia, Paolo, additional, Kater, Arnon P., additional, Chanan-Khan, Asher, additional, Furman, Richard R., additional, O’Brien, Susan, additional, Yenerel, Mustafa Nuri, additional, Illes, Arpad, additional, Kay, Neil, additional, Garcia-Marco, Jose A., additional, Mato, Anthony, additional, Pinilla-Ibarz, Javier, additional, Seymour, John F., additional, Lepretre, Stephane, additional, Stilgenbauer, Stephan, additional, Robak, Tadeusz, additional, Patel, Priti, additional, Higgins, Kara, additional, Sohoni, Sophia, additional, and Jurczak, Wojciech, additional

Published
2021
Full Text
View/download PDF

37. CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia

Author

Byrd, John C., primary, Hillmen, Peter, additional, Ghia, Paolo, additional, Kater, Arnon P., additional, Chanan-Khan, Asher, additional, Furman, Richard R., additional, O’Brien, Susan, additional, Yenerel, Mustafa Nuri, additional, Illes, Arpad, additional, Kay, Neil, additional, Garcia-Marco, Jose A., additional, Mato, Anthony, additional, Pinilla-Ibarz, Javier, additional, Seymour, John F., additional, Lepretre, Stephane, additional, Stilgenbauer, Stephan, additional, Robak, Tadeusz, additional, Patel, Priti, additional, Higgins, Kara, additional, Sohoni, Sophia, additional, and Jurczak, Wojciech, additional

Published
2021
Full Text
View/download PDF

38. Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Author

Pavlova, Sarka, Malcikova, Jitka, Radova, Lenka, Bonfiglio, Silvia, Cowland, Jack B., Brieghel, Christian, Andersen, Mette Klarskov, Karypidou, Maria, Biderman, Bella V, Doubek, Michael, Lazarian, Gregory, Rapado, Inmaculada, Vynck, Matthijs, Porret, Naomi, Andres, Martin, Rosenberg, Dina, Sahar, Dvora, Martinez-Laperche, Carolina, Borde, Ismael Buño, Hindley, Andrew, Sánchez, Julio Bravo, García-Marco, José, Serrano, Alicia, Ferrer Lores, Blanca, Fernández-Rodriguez, Concepción, Bellosillo, Beatriz, Stilgenbauer, Stephan, Tausch, Eugen, Nikdin, Hero, Quinn, Fiona, Atkinson, Emer, Van De Corput, Lisette, Yildiz, Cafer, Bilbao, Cristina, Florido, Yanira, Thiede, Christian, Schuster, Caroline, Stoj, Anastazja, Czekalska, Sylwia, Chatzidimitriou, Anastasia, Laidou, Stamatia, Bidet, Audrey, Dussiau, Charles, Nollet, Friedel, Piras, Giovanna, Borosova, Tereza, Kurucova, Terezia, Monne, Maria, Smirnova, Svetlana, Nikitin, Evgeny, Sloma, Ivan, Delfau, Marie-Helene, Largeaud, Laetitia, Ysebaert, Loic, Valk, Peter J. M., Christian, Amy, Walewska, Renata, Sebastião, Marta, da Silva, Maria Gomes, Galieni, Piero, Angelini, Mario, Rossi, Davide, Spina, Valeria, Matos, Sónia, Martins, Vânia, Donaldson, David, Stoklosa, Tomasz, Pepek, Monika, Baliakas, Panagiotis, Andreu, Rafa, Luna, Irene, Kahre, Tiina, Murumets, Ülle, Laird, Sophie, Ward, Daniel, Alcoceba, Miguel, Balanzategui, Ana, Scarfo, Lydia, Gandini, Francesca, Zapparoli, Ettore, Blanco, Adoracion, Costa, Pau Abrisqueta, Rodriguez, Ana E., Benito Sanchez, Maria Rocio, Davi, Frédéric, Bravetti, Clothilde, Gameiro, Paula, Martinez-Lopez, Joaquin, Tazon, Barbara, Baran-Marszak, Fanny, Davies, Zadie, Caterwood, Mark, Sudarikov, Andrey B, Rosenquist, Richard, Niemann, Carsten Utoft, Stamatopoulos, Kostas, Ghia, Paolo, and Pospisilova, Sarka

Published
2023
Full Text
View/download PDF

39. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas Kapetanakis, Anargyros Scarfo, Lydia and Karakatsoulis, Georgios Allsup, David Alonso Cabrero, Alejandro Andres, Martin Antic, Darko Baile, Monica and Baliakas, Panagiotis Bron, Dominique Capasso, Antonella and Chatzileontiadou, Sofia Cordoba, Raul Correa, Juan-Gonzalo and Cuellar-Garcia, Carolina De Paoli, Lorenzo De Paolis, Maria Rosaria Del Poeta, Giovanni Demosthenous, Christos Dimou, Maria Donaldson, David Doubek, Michael Efstathopoulou, Maria and Eichhorst, Barbara El-Ashwah, Shaimaa Enrico, Alicia and Espinet, Blanca Farina, Lucia Ferrari, Angela Foglietta, Myriam Frederiksen, Henrik Furstenau, Moritz Garcia-Marco, Jose A. Garcia-Serra, Rocio Gentile, Massimo Gimeno, Eva and Glenthoj, Andreas da Silva, Maria Gomes Gutwein, Odit and Hakobyan, Yervand K. Herishanu, Yair Angel Hernandez-Rivas, Jose and Herold, Tobias Innocenti, Idanna Itchaki, Gilad Jaksic, Ozren Janssens, Ann Kalashnikova, Olga B. Kalicinska, Elzbieta Karlsson, Linda Katharina Kater, Arnon P. Kersting, Sabina Labrador, Jorge Lad, Deepesh Laurenti, Luca and Levin, Mark-David Lista, Enrico Lopez-Garcia, Alberto and Malerba, Lara Marasca, Roberto Marchetti, Monia Marquet, Juan Mattsson, Mattias Mauro, Francesca R. Milosevic, Ivana and Miras, Fatima Morawska, Marta Motta, Marina Munir, Talha and Murru, Roberta Niemann, Carsten U. Rodrigues, Raquel Nunes and Olivieri, Jacopo Orsucci, Lorella Papaioannou, Maria and Arturo Pavlovsky, Miguel Piskunova, Inga Popov, Viola Maria and Quaglia, Francesca Maria Quaresmini, Giulia Qvist, Kristian and Reda, Gianluigi Rigolin, Gian Matteo Ruchlemer, Rosa and Saghumyan, Gevorg Shrestha, Amit Simkovic, Martin Spacek, Martin Sportoletti, Paolo Stanca, Oana Stavroyianni, Niki and Tadmor, Tamar Te Raa, Doreen Tonino, Sanne H. Trentin, Livio Van der Spek, Ellen van Gelder, Michel van Kampen, Roel Varettoni, Marzia Visentin, Andrea Vitale, Candida and Wasik-Szczepanek, Ewa Wrobel, Tomasz Yanez San Segundo, Lucrecia and Yassin, Mohamed Coscia and Chatzikonstantinou, Thomas Kapetanakis, Anargyros Scarfo, Lydia and Karakatsoulis, Georgios Allsup, David Alonso Cabrero, Alejandro Andres, Martin Antic, Darko Baile, Monica and Baliakas, Panagiotis Bron, Dominique Capasso, Antonella and Chatzileontiadou, Sofia Cordoba, Raul Correa, Juan-Gonzalo and Cuellar-Garcia, Carolina De Paoli, Lorenzo De Paolis, Maria Rosaria Del Poeta, Giovanni Demosthenous, Christos Dimou, Maria Donaldson, David Doubek, Michael Efstathopoulou, Maria and Eichhorst, Barbara El-Ashwah, Shaimaa Enrico, Alicia and Espinet, Blanca Farina, Lucia Ferrari, Angela Foglietta, Myriam Frederiksen, Henrik Furstenau, Moritz Garcia-Marco, Jose A. Garcia-Serra, Rocio Gentile, Massimo Gimeno, Eva and Glenthoj, Andreas da Silva, Maria Gomes Gutwein, Odit and Hakobyan, Yervand K. Herishanu, Yair Angel Hernandez-Rivas, Jose and Herold, Tobias Innocenti, Idanna Itchaki, Gilad Jaksic, Ozren Janssens, Ann Kalashnikova, Olga B. Kalicinska, Elzbieta Karlsson, Linda Katharina Kater, Arnon P. Kersting, Sabina Labrador, Jorge Lad, Deepesh Laurenti, Luca and Levin, Mark-David Lista, Enrico Lopez-Garcia, Alberto and Malerba, Lara Marasca, Roberto Marchetti, Monia Marquet, Juan Mattsson, Mattias Mauro, Francesca R. Milosevic, Ivana and Miras, Fatima Morawska, Marta Motta, Marina Munir, Talha and Murru, Roberta Niemann, Carsten U. Rodrigues, Raquel Nunes and Olivieri, Jacopo Orsucci, Lorella Papaioannou, Maria and Arturo Pavlovsky, Miguel Piskunova, Inga Popov, Viola Maria and Quaglia, Francesca Maria Quaresmini, Giulia Qvist, Kristian and Reda, Gianluigi Rigolin, Gian Matteo Ruchlemer, Rosa and Saghumyan, Gevorg Shrestha, Amit Simkovic, Martin Spacek, Martin Sportoletti, Paolo Stanca, Oana Stavroyianni, Niki and Tadmor, Tamar Te Raa, Doreen Tonino, Sanne H. Trentin, Livio Van der Spek, Ellen van Gelder, Michel van Kampen, Roel Varettoni, Marzia Visentin, Andrea Vitale, Candida and Wasik-Szczepanek, Ewa Wrobel, Tomasz Yanez San Segundo, Lucrecia and Yassin, Mohamed Coscia

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

Published
2021

40. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfo, Lydia, Karakatsoulis, Georgios, Allsup, David, Alonso Cabrero, Alejandro, Andres, Martin, Antic, Darko, Baile, Monica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuellar-Garcia, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Furstenau, Moritz, Garcia-Marco, Jose A., Garcia-Serra, Rocio, Gentile, Massimo, Gimeno, Eva, Glenthoj, Andreas, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Angel Hernandez-Rivas, Jose, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicinska, Elzbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Miras, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Arturo Pavlovsky, Miguel, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wrobel, Tomasz, Yanez San Segundo, Lucrecia, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foa, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, Ghia, Paolo, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfo, Lydia, Karakatsoulis, Georgios, Allsup, David, Alonso Cabrero, Alejandro, Andres, Martin, Antic, Darko, Baile, Monica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuellar-Garcia, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Furstenau, Moritz, Garcia-Marco, Jose A., Garcia-Serra, Rocio, Gentile, Massimo, Gimeno, Eva, Glenthoj, Andreas, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Angel Hernandez-Rivas, Jose, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicinska, Elzbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Miras, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Arturo Pavlovsky, Miguel, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wrobel, Tomasz, Yanez San Segundo, Lucrecia, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foa, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

Published
2021

41. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.

Author

Byrd, John C., primary, Hillmen, Peter, additional, Ghia, Paolo, additional, Kater, Arnon P., additional, Chanan-Khan, Asher Alban Akmal, additional, Furman, Richard R., additional, O'Brien, Susan M., additional, Yenerel, Mustafa Nuri, additional, Illés, Árpád, additional, Kay, Neil E., additional, Garcia Marco, Jose Antonio, additional, Mato, Anthony R., additional, Seymour, John Francis, additional, Leprêtre, Stephane, additional, Stilgenbauer, Stephan, additional, Robak, Tadeusz, additional, Patel, Priti, additional, Higgins, Kara, additional, Sohoni, Sophia, additional, and Jurczak, Wojciech, additional

Published
2021
Full Text
View/download PDF

45. Bone Marrow Infiltration at Diffuse Large B-Cell Lymphoma NOS Diagnosis: Comparative Study between PET, Histology and Flow Cytometry

Author

Martin Moro, Fernando, primary, Piris-Villaespesa, Miguel, additional, Marquet Palomanes, Juan, additional, Lopez Prieto, Claudia, additional, Herrera, Federico Santiago, additional, Delgado Trillo, Maria Isabel, additional, Garcia-Cosio, Monica, additional, Martinez Lorca, Alberto, additional, Lario Arribas, Ana, additional, Roldan Santiago, Ernesto, additional, Rodriguez Martin, Eulalia, additional, Garcia-Marco, Jose A., additional, Lopez Jimenez, Javier, additional, and Garcia Vela, Jose Antonio, additional

Published
2020
Full Text
View/download PDF

49. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia:a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Scarfò, Lydia, Chatzikonstantinou, Thomas, Rigolin, Gian Matteo, Quaresmini, Giulia, Motta, Marina, Vitale, Candida, Garcia-Marco, Jose Antonio, Hernández-Rivas, José Ángel, Mirás, Fatima, Baile, Mónica, Marquet, Juan, Niemann, Carsten U., Reda, Gianluigi, Munir, Talha, Gimeno, Eva, Marchetti, Monia, Quaglia, Francesca Maria, Varettoni, Marzia, Delgado, Julio, Iyengar, Sunil, Janssens, Ann, Marasca, Roberto, Ferrari, Angela, Cuéllar-García, Carolina, Itchaki, Gilad, Špaček, Martin, De Paoli, Lorenzo, Laurenti, Luca, Levin, Mark David, Lista, Enrico, Mauro, Francesca R., Šimkovič, Martin, Van Der Spek, Ellen, Vandenberghe, Elisabeth, Trentin, Livio, Wasik-Szczepanek, Ewa, Ruchlemer, Rosa, Bron, Dominique, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Farina, Lucia, Foglietta, Myriam, Gentile, Massimo, Herishanu, Yair, Herold, Tobias, Jaksic, Ozren, Kater, Arnon P., Kersting, Sabina, Malerba, Lara, Orsucci, Lorella, Popov, Viola Maria, Sportoletti, Paolo, Yassin, Mohamed, Pocali, Barbara, Barna, Gabor, Chiarenza, Annalisa, dos Santos, Gimena, Nikitin, Eugene, Andres, Martin, Dimou, Maria, Doubek, Michael, Enrico, Alicia, Hakobyan, Yervand, Kalashnikova, Olga, Ortiz Pareja, Macarena, Papaioannou, Maria, Rossi, Davide, Shah, Nimish, Shrestha, Amit, Stanca, Oana, Stavroyianni, Niki, Strugov, Vladimir, Tam, Constantine, Zdrenghea, Mihnea, Coscia, Marta, Stamatopoulos, Kostas, Rossi, Giuseppe, Rambaldi, Alessandro, Montserrat, Emili’, Foà, Robin, Cuneo, Antonio, Ghia, Paolo, Scarfò, Lydia, Chatzikonstantinou, Thomas, Rigolin, Gian Matteo, Quaresmini, Giulia, Motta, Marina, Vitale, Candida, Garcia-Marco, Jose Antonio, Hernández-Rivas, José Ángel, Mirás, Fatima, Baile, Mónica, Marquet, Juan, Niemann, Carsten U., Reda, Gianluigi, Munir, Talha, Gimeno, Eva, Marchetti, Monia, Quaglia, Francesca Maria, Varettoni, Marzia, Delgado, Julio, Iyengar, Sunil, Janssens, Ann, Marasca, Roberto, Ferrari, Angela, Cuéllar-García, Carolina, Itchaki, Gilad, Špaček, Martin, De Paoli, Lorenzo, Laurenti, Luca, Levin, Mark David, Lista, Enrico, Mauro, Francesca R., Šimkovič, Martin, Van Der Spek, Ellen, Vandenberghe, Elisabeth, Trentin, Livio, Wasik-Szczepanek, Ewa, Ruchlemer, Rosa, Bron, Dominique, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Farina, Lucia, Foglietta, Myriam, Gentile, Massimo, Herishanu, Yair, Herold, Tobias, Jaksic, Ozren, Kater, Arnon P., Kersting, Sabina, Malerba, Lara, Orsucci, Lorella, Popov, Viola Maria, Sportoletti, Paolo, Yassin, Mohamed, Pocali, Barbara, Barna, Gabor, Chiarenza, Annalisa, dos Santos, Gimena, Nikitin, Eugene, Andres, Martin, Dimou, Maria, Doubek, Michael, Enrico, Alicia, Hakobyan, Yervand, Kalashnikova, Olga, Ortiz Pareja, Macarena, Papaioannou, Maria, Rossi, Davide, Shah, Nimish, Shrestha, Amit, Stanca, Oana, Stavroyianni, Niki, Strugov, Vladimir, Tam, Constantine, Zdrenghea, Mihnea, Coscia, Marta, Stamatopoulos, Kostas, Rossi, Giuseppe, Rambaldi, Alessandro, Montserrat, Emili’, Foà, Robin, Cuneo, Antonio, and Ghia, Paolo

Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results